Dr. agarwal's health care Limited has announced its schedule for the third quarter financial results disclosure and investor engagement activities. The healthcare services company will conduct its board meeting and earnings call in early February 2026 to discuss its performance for the quarter and nine months ended December 31, 2025.

Board Meeting and Financial Results Approval

The company's Board of Directors is scheduled to meet on Tuesday, February 03, 2026, to consider and approve the unaudited financial results for both standalone and consolidated operations. These results will cover the quarter and nine months ended December 31, 2025, representing the third quarter of the fiscal year 2026.

Earnings Conference Call Schedule

Following the board meeting, Dr. Agarwal's Health Care Limited will host an earnings and analyst conference call on Wednesday, February 04, 2026. The call is scheduled from 11:30 AM IST to 12:30 PM IST and will focus on discussing the financial results with investors and analysts.

Key Participants

The company will be represented by senior management during the conference call:

• Dr. Adil Agarwal – Whole-time Director and Chief Executive Officer
• Mr. Yashwanth Venkat – Chief Financial Officer
• Ms. Aashna Dharia – Head, Investor Relations

Conference Call Access Details

Investors and analysts can join the earnings call through multiple channels. The company has provided comprehensive dial-in options for both domestic and international participants.

International Dial-in Numbers

The company has arranged toll-free numbers for international participants across multiple countries including the USA (18667462133), UK (08081011573), Singapore (8001012045), and several European and Asian markets. A complete list of international numbers has been provided for participants from Argentina, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Poland, South Korea, Sweden, and Thailand.

Regulatory Compliance and Trading Window

In accordance with the company's Code of Conduct for Prevention of Insider Trading, the trading window will remain closed until 48 hours after the announcement of the financial results. This measure ensures compliance with insider trading regulations and maintains market integrity during the results disclosure period.

The announcement has been made pursuant to Regulation 29 and 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additional information regarding the earnings call is available on the company's official website at dragarwals.co.in.

Dr. Agarwal's Health Care Limited has announced a promoter shareholding change through an inter-se transfer between promoter group members. The transaction involves the transfer of equity shares from Dr. Adil Agarwal to Dr. Amar Agarwal by way of gift, executed on December 31, 2025.

Share Transfer Details

The inter-se transfer involved 5,12,473 equity shares, representing 0.16% of the company's total share capital. This transaction was structured as a gift between promoter group members and falls under the regulatory framework of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Pattern Changes

Following the transaction, Dr. Amar Agarwal's shareholding in the company has increased from 4.29% to 4.46%. The change reflects an increase of 0.16% in his voting rights and overall stake in the healthcare company, while Dr. Adil Agarwal's shareholding decreased correspondingly.

Company Capital Structure

The company's equity share capital remains unchanged at ₹31.65 crores, consisting of 31,64,70,002 equity shares of Re. 1 each. The total diluted share capital also stands at the same level, indicating no outstanding convertible securities or warrants that could impact the shareholding calculations.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dr. Amar Agarwal submitted the required documentation to both the National Stock Exchange of India Limited and BSE Limited on January 2, 2026, ensuring full regulatory compliance for the inter-se transfer transaction.

The company's shares continue to be listed on both NSE and BSE, with the transfer not affecting the overall promoter group shareholding but only redistributing shares within the promoter group members.